BL-2050

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameBL-2050
Drug Alias Nameperipheral vascular disease therapy (BioLineRx)BL-2050
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiogenesis modulators
TargetsUpdating
Therapy Area/IndicationsPeripheral Vascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRamot At Tel Aviv University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiolinerx LtdRamot At Tel Aviv University
Active IndicationsN/A
Inactive IndicationsPeripheral Vascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A